Braxia (BRAX.C) announces first multi-dose psilocybin trial in Canada Post date August 27, 2021 Posted by Piers Eaton Posted in brax.c, braxia, braxia scientific, CRTCE, Multi-Dose, Mushrooms, psilocybin, Psychedelics Comments 0
Braxia (BRAX.C) announces first multi-dose psilocybin trial in Canada Post date August 27, 2021 Posted by Piers Eaton Posted in brax.c, braxia, braxia scientific, CRTCE, Multi-Dose, Mushrooms, psilocybin, Psychedelics Comments 0
Braxia (BRAX.C) announces first multi-dose psilocybin trial in Canada Post date August 27, 2021 Posted by Piers Eaton Posted in brax.c, braxia, braxia scientific, CRTCE, Multi-Dose, Mushrooms, psilocybin, Psychedelics Comments 0
Braxia (BRAX.C) announces first multi-dose psilocybin trial in Canada Post date August 27, 2021 Posted by Piers Eaton Posted in brax.c, braxia, braxia scientific, CRTCE, Multi-Dose, Mushrooms, psilocybin, Psychedelics Comments 0
Braxia Scientific (BRAX.C) CEO and Chief Medical Officer receive $918,000 grant to study ketamine assisted iCBT Post date July 28, 2021 Posted by Piers Eaton Posted in Biotech, brax.c, braxia, braxia scientific, CBT, CIHR, Cognitive Behavioral Therapy, CRTCE, Eaton, Government grant, Health Science, iCBT, IV, Psychedelics, Scribes Comments 0